Evommune (EVMN) Long-Term Investments (2025 - 2026)

Evommune (EVMN) has reported Long-Term Investments for 2 consecutive years, with $95.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments changed N/A year-over-year to $95.5 million; the TTM figure through Mar 2026 stood at $95.5 million (changed N/A YoY), while the FY2025 annual figure was $67.5 million, changed N/A from the prior year.
• Long-Term Investments climbed to $95.5 million in Q1 2026 per EVMN's latest filing, from $67.5 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $95.5 million in Q1 2026 and bottomed at $67.5 million in Q4 2025.